Study on Novel Strategies for Cervical Cancer Screening Using Photoelectric Detection and Epigenetic Procotol

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-65
SponsorPeking Union Medical College Hospital

About this trial

A national multicenter, open randomized controlled study was conducted. It is planned to invite 30 multi-center units across the country to compete for enrollment, and each multi-center will enroll 140 patients meeting colposcopic indications (70 in the conventional group and 70 in the experimental group), totaling 4200 patients. Enrolled subjects were randomly divided into two groups. Methylation test + colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test + colposcopic biopsy +OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results. To verify the effectiveness of methylation tests and OITS in screening for CIN2+, whether they can reduce missed diagnosis of CIN2+, whether they can flag excessive colposcopic procedures, and the value of clinical follow-up for cervical lesions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women between the ages of 18 and 65 who have already had sex life

HPV16, 18 positive or high-risk HPV infection with cytology ≧ASC-US

No history of cervical cancer and cervical physical therapy, a complete cervix

No menstrual period, no sexual activity and vaginal medication within 48 hours

Disqualifiers

Cervical dysplasia (congenital malformation or double uterus, etc.)

History of cervical treatment (coning, ablation, or photodynamic therapy)

There are definite immunosuppression conditions, such as HIV infection or organ transplantation

Patients with severe bleeding diseases such as coagulation abnormalities or photosensitive diseases (such as porphyria, lupus erythematosus, etc.)

Trial population

There are 30 multi-center units in the country, and each center competes to enter the group. The accuracy of OITS early data was 75%, the sensitivity was 82%, and the specificity was 63%. According to 20% shedding, possible causes of shedding: error caused by severe inflammatory patients, error caused by improper operation or subjects unwilling to cooperate with follow-up. The optimal efficacy test was performed with the rate of 0.75 in the experimental group and 0.5 in the control group, and the optimal efficacy threshold was 0.1(control-experimental group), bilateral alpha was 0.05, beta was 0.2, and the sample size ratio of the two groups was 1(experimental group: Control group), each single center needs to collect 58 cases in the experimental group and 58 cases in the control group. Considering 20% shedding, the sample size of each single center is at least 70 cases in the experimental group and 70 cases in the control group, and a total of 4200 cases of all centers.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • photoelectric detection

    Diagnostic test

    Methylation test and colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test and colposcopic biopsy and OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results.

Treatment groups

4,200 Participants
are divided into 2 treatment groups
Group A: control group0 interventions
Group B: OITS group1 intervention

Trial outcomes

Primary outcomes

1

Sensitivity and specificity of a photoelectric image detector for cervical lesions

Sensitivity and specificity of the photoelectric detection technique relative to histopathological findings.

Time frame
Enrolled subjects receive histopathological results approximately 7 days after colposcopy

Secondary outcomes

1

Detection rate of CIN2+ by photoelectric cervical lesion image detector

The sensitivity, specificity, CIN2+ detection rate, negative predictive value and positive predictive value were compared with the results of Methylaiton, colpscopy, HPV detection and cytology.

Time frame
Enrolled subjects receive histopathological results approximately 7 days after colposcopy.

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: